ホーム>>Signaling Pathways>> Neuroscience>> Serotonin Transporter>>Azaphen dihydrochloride monohydrate

Azaphen dihydrochloride monohydrate

カタログ番号GC35444

ピポフェジン(アザフェンまたはアザフェン)は、セロトニンの再取り込みの強力な阻害剤です。

Products are for research use only. Not for human use. We do not sell to patients.

Azaphen dihydrochloride monohydrate 化学構造

Cas No.: 63302-99-8

サイズ 価格 在庫数 個数
100mg
$110.00
在庫あり
500mg
$266.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Pipofezine(Azafen or Azaphen) is a potent inhibitor of the reuptake of serotonin. IC50 Value: Target: SSRIsPipofezine is a tricyclic antidepressant (TCA) approved in Russia for the treatment ofdepression. In addition to its antidepressant action, pipofezine has sedative effects as well, indicating antihistamine activity.

[1]. Shinaev NN, Akzhigitov RG. Azaphen: a return to clinical practice.Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(10):55-6. [2]. Ignatowicz L, Ignatowicz R, Wdowiak MW, Jaremko A. Azaphen in the treatment of enuresis in children.Psychiatr Pol. 1977 Jan-Feb;11(1):29-33. [3]. Liberman SS, Sharova SA. A comparison of the effect of the tricyclic antidepressants azaphen and imizin on the gastrointestinal tracts of experimental animals.Farmakol Toksikol. 1975 Jan-Feb;38(1):29-32. [4]. Misurec J, NÁhunek K, KamenickÁ V, Chmelar M. Proceedings: Influence of azaphen, a new antidepressive drug, on the human EEG. Act Nerv Super (Praha). 1974;16(4):245-6.

レビュー

Review for Azaphen dihydrochloride monohydrate

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Azaphen dihydrochloride monohydrate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.